Future pharmacological treatment of cystic fibrosis

Respiration

Volumn 67, Issue 4, 2000, Pages 351-357

  Zeitlin, Pamela L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CFTR; Chaperones; Chloride channels

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC G 418; BUTYRIC ACID; CHAPERONE; CHLORIDE; FLAVONOID; GENISTEIN; GENTAMICIN; MESSENGER RNA; MILRINONE; MUTANT PROTEIN; PHOSPHODIESTERASE INHIBITOR;

AUTOSOMAL RECESSIVE DISORDER; CHLORIDE TRANSPORT; ENDOPLASMIC RETICULUM; GENE CONTROL; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENOTYPE; HUMAN; LUNG FIBROSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; RNA TRANSLATION; STOP CODON;

EID: 0033840119     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000029528     Document Type: Review

References (67)

1. Rosenstein BJ: What is a cystic fibrosis diagnosis? Clin Chest Med 1998;19:423-441.
2. Brown CR, Hong-Brown LQ, Welch WJ: Strategics for correcting the delta F508 CFTR protein-folding detect. J Bioenerg Biomembr 1997;29:491-502.
3. Kartner N, Augustinas O, Jensen TJ, Naismith AL, Riordan JR: Mislocalization of delta F508 CFTR in cystic fibrosis sweat gland. Nat Genet 1992;1:321-327.
4. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O'Riordan CR, Smith AE: Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990;63:827-834.
5. Anderson MP, Rich DP, Gregory RJ, Smith AE, Welsh MJ: Generation of cAMP-activated chloride currents by expression of CFTR. Science 1991;251:679-682.
6. - channels in CF: Lack of activation by protein kinase C and cAMP-dependent protein kinase. Science 1989;244:1351-1353.
7. Ismailov II, Awayda MS, Jovov B, Berdiev BK, Fuller CM, Dedman JR, Kaetzel M, Benos DJ: Regulation of epithelial sodium channels by the cystic fibrosis transmembrane conductance regulator. J Biol Chem 1996;271:4725-4732.
8. + channels in mouse CCD cells. Am J Physiol 1997;272:C657-C666.
9. + channels by protein kinase A corrected by insertion of CFTR (see comments). Nature 1992;358:581-584.
10. Gabriel SE, Clarke LL, Boucher RC, Stutts MJ: CFTR and outward rectifying chloride channels are distinct proteins with a regulatory relationship. Nature 1993;363:263-268.
11. Guggino WB: Outwardly rectifying chloride channels and CF: A divorce and remarriage. J Biocnerg Biomembr 1993;25:27-35.
12. Schwiebert EM, Egan ME, Hwang TH, Fulmer SB, Allen SS, Cutting GR, Guggino WB: CFTR regulates outwardly rectifying chloride channels through an autocrine mechanism involving ATP. Cell 1995;81:1063-1073.
13. Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher RC: Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 1992;2:21-25.
14. Mickle JE, Cutting GR: Clinical implications of cystic fibrosis transmembrane conductance regulator mutations; in Fid SB (ed): Cystic Fibrosis. Clin Chest Med. Philadelphia, Saunders, 1999, vol 19, pp 443-458.
15. Haardt M, Benharouga M, Lechardeur D, Kartner N, Lukacs GL: C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation. J Biol Chem 1999;274:21873-21877.
16. Palmer E, Wilhelm JM, Sherman F: Phenotypic suppression of nonsense mutants in yeast by aminoglycoside antibiotics. Nature 1979;277: 148-150.
17. Singh A, Ursic D, Davies J: Phenotypic suppression and misreading Saccharomyces cerevisiae. Nature 1979;277:146-148.
18. Bedwell DM, Kaenjak A, Benos DJ, Bebok Z, Bubien JK, Hong J, Tousson A, Clancy JP, Sorscher EJ: Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1997;3:1280-1284.
19. Howard M, Frizzell RA, Bedwell DM: Aminoglycoside antibiotics restore CFTR function by overcoming premature slop mutations (see comments). Nat Med 1996;2:467-469.
20. Barton-Davis ER, Cordier L, Shoturma DI, Leland SF, Sweeney HL: Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice (see comments). J Clin Invest 1999;104:375-381.
21. Clancy JP, Bcbok Z, Jones J, Walker L, King C, Greer H, Wing L, Lyrene R, Sorscher EJ, Bedwell DM: A controlled trial of gentamicin to suppress premature stop codons in CF patients (abstract). Pediatr Pulmonol 1999;S19:239-240.
22. Wilschanski M, Famini C, Blau H, Rivlin J, Augarten A, Avital A, Kerem B, Kerem E: A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 2000;161:860-865.
23. Thomas PJ, Pedersen PL: Effects of the delta F508 mutation on the structure, function, and folding of the first nucleotide-binding domain of CFTR. J Bioenerg Biomembr 1993;25:11-19.
24. Thomas PJ, Shenbagamurthi P, Sondek J, Hullihen JM, Pedersen PL: The cystic fibrosis transmembrane conductance regulator. Effects of the most common cystic fibrosis-causing mutation on the secondary structure and stability of a synthetic peptide. J Biol Chem 1992; 267:5727-5730.
25. Ko YH, Thomas PJ, Delannoy MR, Pedersen PL: The cystic fibrosis transmembrane conductance regulator. Overexpression, purification, and characterization of wild type and delta F508 mutant forms of the first nucleotide binding fold in fusion with the maltose-binding protein. J Biol Chem 1993;268:24330-24338.
26. - channel is functional when retained in endoplasmic reticulum of mammalian cells. J Biol Chem 1995;270:12347-12350.
27. Massiah MA, Ko YH, Pedersen PL, Mildvan AS: Cystic fibrosis transmembrane conductance regulator Solution structures of peptides based on the Phc508 region, the most common site of disease-causing AF508 mutation. Biochemistry 1999;38:7453-7461.
28. Moyer BD, Denton J, Karlson KH, Reynolds D, Wang S, Mickle JE, Milcwski M, Cutting GR, Guggino WB, Li M, Stanton BA: A PDZ-interacting domain in CFTR is an apical membrane polarization signal. J Clin Invest 1999; 104:1353-1361.
29. Ameen NA, Martensson B, Bourguinon L, Marino C, Isenberg J, McLaughlin GE: CFTR channel insertion to the apical surface in rat duodenal villus epithelial cells is upregulated by VIP in vivo. J Cell Sci 1999;112:887-894.
30. Prince LS, Workman RBJ, Marchase RB: Rapid endocytosis of the cystic fibrosis transmembranc conductance regulator chloride channel. Proc Natl Acad Sci USA 1994;91:5192-5196.
31. Brown CR, Hong-Brown LQ, Welch WJ: Correcting temperature-sensitive protein folding defects. J Clin Invest 1997;99:1432-1444.
32. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ: Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive (see comments). Nature 1992;358:761-764.
33. Egan ME, Schweibert EM, Guggino WB: Differential expression of ORCC and CFTR induced by low temperature in CF airway epithelial cells. Am J Physiol 1995;268:C243-C251.
34. Jensen TJ, Loo MA, Pind S, Williams DB, Goldberg AL, Riordan JR: Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 1995;83:129-135.
35. Ward CL, Kopito RR: Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. J Biol Chem 1994;269:25710-25718.
36. Sato S, Ward CL, Krouse ME, Wine JJ, Kopito RR: Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 1996;271:635-638.
37. Brown CR, Hong-Brown LQ, Biwersi J, Verkman AS, Welch WJ: Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1996; 1:117-125.
38. Ashkenas J, Byers PH: The final stage of gene expression: Chaperones and the regulation of protein fate. Am J Hum Genet 1997;61:267-272.
39. Jiang C, Fang SL, Xiao YF, O'Connor SP, Nadler SG, Lee DW, Jefferson DM, Kaplan JM, Smith AE, Cheng SH: Partial restoration of cAMP-stimulated CFTR chloride channel activity in ΔF50X eells by deoxyspergualin. Am J Physiol 1998;275:C171-C178.
40. Strickland E, Qu BH, Millen L, Thomas PJ: The molecular chaperone Hsc70 assists the in vitro folding of the N-rerminal nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator. J Biol Chem 1997;272:25421-25424.
41. Pind S, Riordan JR, Williams DB: Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis ot the cystic fibrosis transmembrane conductance regulator. J Biol Chem 1994;269: 12784-12788.
42. Yang Y, Janich S, Cohn JA, Wilson JM: The common variant of cystic fibrosis transmembrane conductance regulator is recognized by Hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc Natl Acad Sci USA 1993;90:9480-9484.
43. Rubenstein RC, Egan ME, Zeitlin PL: In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbuty-rate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 1997;100: 2457-2465.
44. (-) secretion in Calu-3 airway epithelial cells. Am J Physiol 1999;277:L700-L708.
45. Mover BD, Loffing-Cueni D, Loffing J, Reynolds D, Stanton BA: Butyrate increases apical membrane CFTR but reduces chloride secretion in MDCK cells. Am J Physiol 1999;277: F271-F276.
46. Illek B, Zhang L, Lewis NC, Moss RB, Dong JY, Fischer H: Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Am J Physiol 1999;277: C833-C839.
47. Rubenstein RC, Zeitlin PL: Sodium 4-phenylbutyrate downregulates hsc70: Implications for intracellular trafficking of ΔF508-CFTR. Am J Physiol 2000;278:C259-C267.
48. Ostedgaard LS, Zeiher B, Welsh MJ: Processing of CFTR bearing the P574H mutation differs from wild-type and ΔF508-CFTR. J Cell Sci 1999;112:2091-2098.
49. Rubenstein RC, Zeitlin PL: A pilot clinical trial of sodium 4-phenylbutyrate(Huphenyl) in delta F508-homozygous cystic fibrosis patients: Evidence of restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998;157:484-490.
50. Kemp S, Wei HM, Lu JF, Braiterman LT, McGuinness MC, Moser AB, Watkins PA, Smith KD: Gene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy (see comments). Nat Med 1998;4:1261-1268.
51. Perlmutter DH: Alpha-1-antitrypsin deficiency. Semin Liver Dis 1998;18:217-225.
52. Qu D, Teckman JH, Omura S, Perlmutter DM: Degradation of a mutant secretory protein, alpha 1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J Biol Chem 1996:271:22791-22795.
53. Illek B, Fischer H: Flavonoids stimulate Cl conductance of human airway epithelium in vitro and in vivo. Am J Physiol 1998;275: L902-L910.
54. 1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells. Proc Natl Acad Sci USA 1992;89: 5562-5566.
55. Arispe N, Ma J, Jacobson KA, Pollard MB: Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1.3-dipropylxanthine (CPX) and 1.3-diallyl-8-cyclohexylxanthine (DAX). J Biol Chem 1997;273:5727-5734.
56. 1-adenosine-receptor antagonist, regulates intracellular pH in cystic fibrosis cells. Am J Physiol 1995;269:C226-C233.
57. Cohen BE, Lee G, Jacobson KA, Kim YC, Huang Z, Sorscher FJ, Pollard HB: 8-Cyclopentyl-1.3-dipropylxanthine and other xanthines differentially hind to the wild-type and delta F508 first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator. Biochemistry 1997;36:6455-6461.
58. Haws CM, Nepomuceno IB, Krouse ME, Wakelee H, Law T, Xia Y, Nguyen H, Wine JJ: Delta F508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines. Am J Physiol 1996;270:C1544-C1555.
59. Kelley TJ, Al-Nakkash L, Drumm ML: CFTR-mediated chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells. Am J Respir Cell Mol Biol 1995;13:657-664.
60. Kelley TJ, Al-Nakkash L, Cotton CU, Drumm ML: Activation of endogenous ΔF508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition. J Clin Invest 1996;98:513-520.
61. Kelley TJ, Thomas K, Milgram LJ, Drumm ML: In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant ΔF508 in murine nasal epithelium. Proc Natl Acad Sci USA 1997;94:2604-2608.
62. - secretion in G551D cystic fihrosis mutant mice. Am J Physiol 1998;274:C492-C499.
63. - channels. J Biol Chem 1995;270:20466-20472.
64. Wilschanski M, Zielenski J, Markiewicx D, Tsui LC, Corey M, Levison H, Durie PR: Correlation of sweat chloride concentration with classes of the ostic fibrosis transmembrane conductance regulator gene mutations. J Pediatr 1995;127:705-710.
65. Anonymous: Correlation between genotype and phenolypc in patients with cystic fibrosis. The Cystic Fibrosis Genotype-Phenotype Consortium (see comments). N F.ngl J Med 1993; 329:1308-1313.
66. - channels with altered pore properties (see comments). Nature 1993;362:160-164.
67. Claney JP, Ruiz FE, Sorscher FJ: Adenosine and its nucleotides activate wild-type and RI17H CFTR through an A2B receptor-coupled pathway. Am J Physiol 1999;276:C361-C369.